Vasculitides of large vessels;Vaskulitiden der großen Gefäße

Vasa - Journal of Vascular Diseases

Volumn 40, Issue 2, 2011, Pages 89-98

  Caspary, L ^a  

^a Angiologische Praxis Luisenstraße und Gefäßzentrum Klinikum Oststadt   (Germany)

Author keywords

Aortitis; Beh et disease; Giant cell arteritis; Takayasu arteritis; Vascular imaging; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; COLCHICINE; COLECALCIFEROL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEPIRUDIN; METHOTREXATE; PREDNISOLONE; STEROID;

ANEURYSM SURGERY; ANTICOAGULANT THERAPY; AORTA ANEURYSM; AORTA ARCH SYNDROME; AORTITIS; ARTICLE; BEHCET DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY STENOSIS; LARGE VESSEL VASCULITIS; LUNG EMBOLISM; NECROTIZING ARTERITIS; PHLEBITIS; RECURRENT DISEASE; STEROID THERAPY; THROMBOEMBOLISM; TREATMENT DURATION; VASCULITIS; VEIN THROMBOSIS;

ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VASCULITIS;

EID: 79955451284     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000078     Document Type: Article

References (71)

1. Ahn JK, Lee YS, Jeon CH. Treatment of venous thrombosis associated with Behcet's disease: Immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27: 201-205.
2. Alpagut U, Ugurlucan M, Dayioglu E. Major arterial involvement and review of Behcet's disease. Ann Vasc Surg 2007; 21: 232-239.
3. Andrews J, Mason JC. Takayasu's arteritis - recent advances in imaging offer promise. Rheumatology 2007; 46: 6-15.
4. Arend WP, Michel BA, Block DA, Hunder GG, Calabrese LH, Edworthy SM et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134.
5. Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G et al. Is (18)F-fl uorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 2009; 60: 1193-1200.
6. Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 2009; 48: 258-261.
7. Beschorner U, Goebel H, Rastan A, Sixt S, Zeller T. Histological diagnosis of atypical Takayasu arteritis using percutaneous transluminal atherectomy. J Endovasc Ther 2008; 15: 241-243.
8. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434-439.
9. Bley TA, Reinhard M, Hauenstein C, Markl M, Warnatz K, Hetzel A et al. Comparison of duplex sonography and highresolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum 2008; 58: 2574-2578.
10. Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. Curr Opin Rheumatol 2009; 21: 19-28.
11. Blockmans D, Coudyzer W, Vanderschueren S, Stroobants S, Loeckx D, Heye S et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology 2008; 47: 1179-1184.
12. Bongartz T, Matteson EL. Largevessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006; 18: 10-17.
13. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999; 42: 311-317.
14. Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol. 2009; 36: 794-796.
15. Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol 2009; 27 (Suppl 52): S10-S13.
16. Burke AP, Tavora F, Narula N, Tomaszewski JE, Virmani R. Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification. Hum Pathol 2008; 39: 514-526.
17. Chatelain D, Duhaut P, Schmidt J, Loire R, Bosshard S, Guernou M et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visualloss. Ann Rheum Dis 2009; 68: 84-88.
18. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990; 335: 1078-80.
19. Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A et al. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008; 35: 270-277.
20. De Miguel E, Castillo C, Rodríguez A et al. Working Group Ultrasound Giant Cell Arteritis. Learning and reliability of colour Doppler ultrasound in giant cell arteritis. Clin Exp Rheumatol 2009; 27 (Suppl 52): S53-S58.
21. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Int Med 1995; 122: 502-507.
22. Förster S, Tato F, Weis M, Czihal M, Rominger A, Bartenstein P, Hacker M, Hoffmann U. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. Vasa 2011: 40: in press.
23. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annual Rev Immunol 2009; 27: 165-197.
24. García-Martínez A, Hernández-Rodríguez J, Arguis P. Development of aortic aneurysm/dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008; 59: 422-430.
25. Gornik HL, Creager MA. Aortitis. Circulation 2008; 117: 3039-3051.
26. Han JW, Shimada K, Ma-Krupa W et al. Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular infl ammation. Circ Res 2008; 102: 546-553.
27. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009; 68: 1528-1534.
28. Hautzel H, Sander O, Heinzel A, Schneider M, Müller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med 2008; 49: 1107-1113.
29. Hoffmann GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 36: 568-582.
30. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH. Infliximab for maintenance of glucocorticosteroidinduced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-630.
31. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-1128.
32. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum. 1990; 33: 1065-1136.
33. Ioscovich A, Gislason R, Fadeev A, Grisaru-Granovsky S, Halpern S. Peripartum anesthetic management of patients with Takayasu's arteritis: case series and review. Int J Obstet Anesth 2008; 17: 358-364.
34. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 36: 186-192.
35. Kermani TA, Schäfer VS, Crowson CS, Hunder GG, Gabriel SE, Matteson EL, Warrington KJ. Increase in age at onset of giant cell arteritis: A population-based study. Ann Rheum Dis 2010; 69: 780-781.
36. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottam M, Hoffmann GS. Takayasu arteritis. Ann Intern Med 1994; 120: 919-929.
37. Kim WH, Choi D, Kim JS, Ko YG, Jang Y, Shim WH. Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Behçet disease. J Endovasc Ther 2009; 16: 631-63
38. Khoury JA, Hoxworth JM, Mazlumzadeh M, Wellik KE, Wingerchuk DM, Demaerschalk BM. The clinical utility of high resolution magnetic resonance imaging in the diagnosis of giant cell arteritis: a critically appraised topic. Neurologist 2008; 14: 330-33
39. Lee BB, Laredo J, Neville R, Villavicencio JL. Endovascular management of Takayasu arteritis: is it a durable option? Vascular 2009; 17: 138-16.
40. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol 2008; 35: 88-95.
41. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306-3309.
42. Lee SG, Ryu JS, Kim HO, Oh JS, Kim YG, Lee CK, Yoo B. Evaluation of disease activity using F-18 FDG PET-CT in patients with Takayasu arteritis. Clin Nucl Med 2009; 34: 749-752.
43. Linnemann B, Greinacher A, Lindhoff -Last E. Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease. Vasa 2010; 39: 103-107.
44. Liu CW, Ye W, Liu B, Zeng R, Wu W, Dake MD. Endovascular treatment of aortic pseudoaneurysm in Behçet disease. J Vasc Surg 2009; 50: 1025-1030.
45. Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O et al. Population-based prevalence study of Behçet's disease. Differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58: 3951-3959.
46. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, Merkel PA. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-2797.
47. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine 2009; 88: 221-226.
48. Marie I, Proux A, Duhaut P. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine 2009; 88: 182-192.
49. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625-630.
50. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL et al. Treatment of giant cell arteritis using induction therapy with high dose glucocorticoids: a doubleblind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54: 3310-3318.
51. Melikoglu M, Kural-Seyahi E, Tascilar K, Yazici H. The unique features of vasculitis in Behçet's syndrome. Clin Rev Allergy Immunol 2008; 35: 40-46.
52. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffmann GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long term follow-up. Ann Rheum Dis. 2008; 67: 1567-1569.
53. Moriwaki R, Noda M, Yajima M. Clinical manifestations of Takayasu arteritis in India and Japan-new classification of angiographic findings. Angiology 1997; 48: 369-379.
54. Mukhtyar C, Guillevin L, Cid MC. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323.
55. Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996; 35: 1161-1168.
56. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Postinterventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatol 2006; 45 600-605.
57. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology 2008; 47: 403-408.
58. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specifi c Toll-like receptor profiles in human medium and large arteries. Circulation 2008; 118: 1276-1284.
59. Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol 2003; 21 (Suppl 32): S23-S28.
60. Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-1342.
61. Schmidt WA, Nerenheim A, Seipelt E, Poehls C, Gromnica-Ihle EJ. Diagnosis of early Takayasu arteritis by colour Doppler ultrasonography. Rheumatology 2002; 41: 496-502.
62. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in largevessel giant cell arteritis. Rheumatology 2008; 47: 96-101.
63. Tatò F, Hoffmann U. Giant cell arteritis: a systemic vascular disease. Vascular Med 2008; 13: 127-140.
64. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol 2009; 21: 41-46.
65. van Bommel EF, van der Veer SJ, Hendriksz TR, Bleumink GS. Persistent chronic peri-aortitis ("infl ammatory aneurysm") after abdominal aortic aneurysm repair: systematic review of the literature. Vasc Med 2008; 13: 293-303.
66. Watts R, Al-Taiar A, Mooney J et al. The epidemiology of Takayasu arteritis in the UK. Rheumatology 2009; 48: 1008-1011
67. Weyand CM, Goronzy JJ. Mechanisms of disease: Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160-169.
68. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457-466
69. Witz M, Korzets Z. Inflammatory abdominal aortic aneurysms. Isr Med Assoc J 2005; 7: 385-387.
70. Yesilot N, Bahar S, Yilmazer S, Mutlu M, Kurtuncu M, Tuncay R et al. Cerebral venous thrombosis in Behçet's disease compared to those associated with other etiologies. J Neurol 2009; 256: 1134-1142.
71. Zehr KJ, Mathur A, Orszulak TA, Mullany CJ, Schaff HV. Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis. Ann Thorac Surg 2005; 79: 1512-1517.